The Latent Tuberculosis Infection Detection Market Size is valued at USD 1.53 billion in 2023 and is predicted to reach USD 2.37 billion by the year 2031 at a 5.7% CAGR during the forecast period for 2024-2031.
Latent tuberculosis infection (LTBI) detection is a critical component of tuberculosis (TB) control, aiming to prevent the progression to active TB disease. Regular screening and effective detection strategies are vital for reducing TB incidence and controlling outbreaks. The latent tuberculosis infection detection market is experiencing growth due to the rising prevalence of tuberculosis worldwide. Various diagnostic methods, such as tuberculin skin tests, interferon-gamma release assays, and molecular tests, are used to detect latent tuberculosis infection. Factors driving market growth include increased awareness, government initiatives for tuberculosis control, and advancements in diagnostic technologies. Key market players are funding for research and development to introduce innovative detection methods.
The market is expected to continue expanding as healthcare systems focus on early detection and treatment of latent tuberculosis to prevent its progression to active disease. The rising risk of developing active disease from latent tuberculosis infection is one of the major driving factors for market growth. In addition, rising awareness about TB detection and various government initiatives for effective diagnosis and screening of tuberculosis infection are other factors contributing to market expansion.
Competitive Landscape
Some Major Key Players In The Latent Tuberculosis Infection Detection Market:
- QIAGEN
- BIOMÉRIEUX
- Oxford Immunotec
- SD Biosensor, INC.
- Wantai BioPharm
- Lionex GmbH
- Sanofi
- Serum Institute of India Pvt. Ltd
- ARKRAY, Inc.
- Par Pharmaceutical, Inc.
- Abbott,
- Hoffmann-La Roche Ltd,
- Other Market Players
Market Segmentation:
The latent tuberculosis infection detection market segmentation includes segments based on Brand, Test Type, Application, and End-Use. As per the brand segment, the market consists of QFT-Plus (QuantiFERON-TB Gold Plus and Others. Based on Test Type, the market segments include Tuberculin Skin Test (TST) and Interferon Gamma Release Assay (IGRA). Based on Application, the market segments are Household Contacts with Pulmonary TB, PLHIV, and Others. Based on End-users, the market is segmented as Diagnostic Laboratories, Hospitals/Clinics, and Academic & Research Institutions.
The Hospital Segment Can Be Considered A Significant Contributor To The Latent Tuberculosis Infection Detection Market.
The Hospitals/Clinics segment plays a vital role in the latent tuberculosis infection (LTBI) detection market. These healthcare settings are primary locations for diagnosing and managing LTBI due to their access to advanced diagnostic tools and specialized healthcare professionals. Hospitals and clinics conduct screening using methods like the Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs). The growth of this segment is due to the rising prevalence of TB, increasing government and non-government initiatives for TB control, and the emphasis on early detection and treatment. Additionally, hospitals and clinics serve as key centres for implementing TB screening programs, especially in high-risk populations.
The Tuberculin Skin Test (TST) Segment Witnessed Growth At A Rapid Rate.
The tuberculin skin test (TST) segment is a crucial part of the detection market for latent tuberculosis infection (LTBI). It is widely used due to its simplicity, low cost, and established use in clinical practice. Despite its limitations, such as cross-reactivity with BCG vaccination and non-tuberculous mycobacteria, TST remains a standard screening tool, especially in resource-limited settings. The segment is driven by the ongoing need for TB control, government screening programs, and efforts to identify and treat LTBI in high-risk populations.
In The Region, The North American Latent Tuberculosis Infection Detection Market Holds A Significant Revenue Share.
The North American latent tuberculosis infection detection market is projected to obtain the maximum market share. The opportunities in the form of unmet medical needs, scientific research, and economic growth are some primary growth drivers of this market. The rise of the healthcare regulatory scenario in countries is estimated to attract international players to capitalize and invest in existing opportunities. Asia Pacific is to be seen to grow at a rapid rate in the global latent tuberculosis infection detection market industries due to growing concerns about government initiatives and increasing funding in various ways.
Recent Developments:
- In March 2024, QIAGEN formed a cooperation with the International Panel Physicians Association (IPPA) to provide education and assistance to panel physicians throughout the world regarding the most up-to-date tuberculosis screening needs. The primary emphasis will be on the novel IGRA prerequisites and their advantageous implications for patients and healthcare professionals.
Latent Tuberculosis Infection Detection Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 1.53 Bn |
|
Revenue Forecast In 2031 |
USD 2.37 Bn |
|
Growth Rate CAGR |
CAGR of 5.7% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Brand, Test Type, Application, End-Use |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Wantai BioPharm, Lionex GmbH, QIAGEN, BIOMÉRIEUX, Oxford Immunotec, SD Biosensor INC., Sanofi, Serum Institute of India Pvt. Ltd, ARKRAY, Inc., Par Pharmaceutical, Inc., and others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
